MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLTX MoonLake Immunotherapeutics

Post-Mkt 02-25 18:10:54 EST

18.22

+0.02

+0.11%

盘后18.00

-0.22-1.21%

18:06 EST

High19.00	Low17.96	Vol1.37M
Open18.10	D1 Closing18.20	Amplitude5.71%
Mkt Cap1.30B	Tradable Cap736.37M	Total Shares71.37M
T/O24.94M	T/O Rate3.38%	Tradable Shares40.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":18.22,"timestamp":1772053200000,"preClose":18.2,"halted":0,"volume":1365542,"hourTrading":{"tag":"盘后","latestPrice":18,"preClose":18.22,"latestTime":"18:06 EST","volume":47740,"amount":869822.03616,"timestamp":1772060793401,"change":-0.22,"changeRate":-0.012075,"amplitude":0.026043},"delay":0,"changeRate":0.0010989010989010755,"floatShares":40415700,"shares":71373579,"eps":-3.328528,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"02-25 18:10:54 EST","open":18.1,"high":19,"low":17.96,"amount":24944792.68744,"amplitude":0.057143,"askPrice":18.5,"askSize":50,"bidPrice":18,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-3.328528,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772067600000},"marketStatusCode":4,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":18.2,"preHourTrading":{"tag":"盘前","latestPrice":18.2641,"preClose":18.2,"latestTime":"09:28 EST","volume":7682,"amount":139787.525684,"timestamp":1772029709946,"change":0.0641,"changeRate":0.003522,"amplitude":0.020879},"postHourTrading":{"tag":"盘后","latestPrice":18,"preClose":18.22,"latestTime":"18:06 EST","volume":47740,"amount":869822.03616,"timestamp":1772060793401,"change":-0.22,"changeRate":-0.012075,"amplitude":0.026043},"volumeRatio":0.635998,"impliedVol":0.7653,"impliedVolPercentile":0.3984},"requestUrl":"/m/hq/s/MLTX/tweets","defaultTab":"tweets","newsList":[{"id":"2614085617","title":"MoonLake posts FY 2025 interest expense of USD 7.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085617?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:13","pubTimestamp":1772018026,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL230Gml:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2613972711","title":"MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2613972711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613972711?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:54","pubTimestamp":1771937650,"startTime":"0","endTime":"0","summary":"Oppenheimer raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $35 from $30 and keeps an Outperform rating on the shares. Moon...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-price-target-raised-to-35-from-30-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-price-target-raised-to-35-from-30-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","MLTX"],"gpt_icon":0},{"id":"2613715490","title":"MoonLake Immunotherapeutics : Leerink Partners Raises Target Price to $24 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715490?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK0XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2613794758","title":"MoonLake Immunotherap Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613794758?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:05","pubTimestamp":1771927500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 05:05 ET (10:05 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2613773404","title":"Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept","url":"https://stock-news.laohu8.com/highlight/detail?id=2613773404","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613773404?lang=en_us&edition=fundamental","pubTime":"2026-02-24 03:58","pubTimestamp":1771876684,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) has an average rating of overweight and mean price target of $22.21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic rese","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLTX"],"gpt_icon":0},{"id":"2613731132","title":"Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and PROCEPT BioRobotics (PRCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613731132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613731132?lang=en_us&edition=fundamental","pubTime":"2026-02-24 02:30","pubTimestamp":1771871408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-and-procept-biorobotics-prct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-and-procept-biorobotics-prct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4585","BK4581","XLV","MLTX","XBI","BK4139","BK4588","HCSG","LABU","LU2324357040.USD","LU0029874061.USD","PRCT","BK4082","BK4137"],"gpt_icon":0},{"id":"2613006787","title":"BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase","url":"https://stock-news.laohu8.com/highlight/detail?id=2613006787","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613006787?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:10","pubTimestamp":1771855800,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan ChaseEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL6N3ZJ0FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTCI","SWR.UK","GOU","SW","GOOX","RTYY","D","IMRA","EHAB","HL","VRE","VFC","DE","GOOGL","PPL","ACLX","LDOS","FRSH","JPMO","MRAL","FBIN","VNDA","ED","INMD","CNP","ELIS","WDAY","MLTX","ELIL","MNDY","IP","SEM","WGS","RIOX","YSS","FRPT","DPZ","DOCU","MRK","FIAT","CDE","ITRI","PKG","JPM","RIOT","ICOI"],"gpt_icon":1},{"id":"2613782138","title":"BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782138","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782138?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:21","pubTimestamp":1771852903,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo NordiskEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL6N3ZJ0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COIW","ICOI","COIO","LU1935042991.SGD","LU2265009873.SGD","LLYX","MARO","ACLX","BK4600","CONX","MNDY","COYY","IMRA","MAAY","LU0158827948.USD","VNDA","WDAY","RIOT","ELIS","CONY","ELIL","COIG","FRSH","LDOS","IE00BWXC8680.SGD","LLII","RIOX","LU2112291526.USD","FIAT","LLY","MRK","MLTX","MRAL","COIA","LU2746668461.USD","DPZ","LU0109394709.USD","LLYZ","CONI","RTYY","HL","COII","DE","VFC","FBIN","CDE","DOCU"],"gpt_icon":1},{"id":"2613878668","title":"MoonLake Immunotherapeutics - Remaining Tranches Provide up to $400 Mln Future Funding - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2613878668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613878668?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:05","pubTimestamp":1771844735,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZJ0KB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2613865267","title":"MoonLake Immunotherapeutics - Enters First Amendment to Loan and Security Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2613865267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613865267?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:05","pubTimestamp":1771844735,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZJ0KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2613200796","title":"MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2613200796","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613200796?lang=en_us&edition=fundamental","pubTime":"2026-02-23 16:56","pubTimestamp":1771836964,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics  said Sunday that a mid-stage clinical trial of its experimental drug, SLK, for patients with axial spondyloarthritis, a chronic inflammatory disease that affects the spine and joints, showed significant improvement in symptoms.The drugmaker said 81% of the 26 patients receiving SLK experienced significant symptom improvement after 12 weeks of treatment.More than 80% of participants also showed meaningful reductions in overall disease activity, the company said. It added that imaging scans revealed reduced inflammation in patients' joints, including deeper tissues that are often difficult to treat.The company said additional scans suggested the drug may help slow bone changes that can lead to permanent stiffness and joint damage.As of Dec. 31, the company reported $394 million in cash and short-term investments, which it expects will fund operations into H2 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2613798262","title":"MoonLake announces results from Phase 2 trial of Sonelokimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2613798262","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613798262?lang=en_us&edition=fundamental","pubTime":"2026-02-23 03:15","pubTimestamp":1771787748,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) announces topline results from the S-OLARIS Phase 2 trial of SLK in patients with radiographic and non-radiograp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-announces-results-from-phase-2-trial-of-sonelokimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-announces-results-from-phase-2-trial-of-sonelokimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2613763032","title":"Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Guardant Health (GH) and Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613763032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613763032?lang=en_us&edition=fundamental","pubTime":"2026-02-23 02:10","pubTimestamp":1771783853,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-guardant-health-gh-and-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-guardant-health-gh-and-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XLV","BK4585","BK4551","BCAX","LABU","LU0128526141.USD","BK4535","BK4581","LU0029874061.USD","BK4196","HCSG","BK4139","BK4137","XBI","MLTX","GH"],"gpt_icon":0},{"id":"2613127341","title":"MoonLake Q4 R&D expense USD 56 million, down 7.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613127341","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613127341?lang=en_us&edition=fundamental","pubTime":"2026-02-23 00:00","pubTimestamp":1771776019,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics reported Q4 2025 and FY 2025 results, ending 2025 with cash, cash equivalents and short-term marketable debt securities of USD 394 million. R&D expenses were USD 56 million in Q4 2025, while G&A expenses were USD 9.2 million. The company said its cash position is expected to fund operating expenses and capital expenditure requirements into H2 2027, and it amended its debt facility with Hercules Capital, including a USD 25 million drawdown and up to USD 400 million in non-dilutive funds remaining available. Alongside the earnings release, MoonLake announced positive topline Phase 2 S-OLARIS data for sonelokimab in axial spondyloarthritis, with 81% of treated patients achieving ASAS40 at Week 12 and more than 80% achieving a clinically important improvement on ASDAS-CRP by Week 12, supported by SPARCC MRI and PET imaging findings. MoonLake also confirmed an Investor Day webcast for February 23, 2026, and reiterated anticipated milestones including 52-week VELA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nNDL3bclp8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","BK4588","NDAQ","LU2210150020.SGD","BK4585","MLTX","BK4112","SG9999014013.SGD","IE00BGHQF748.EUR","HTGC","BK4135","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2613273445","title":"MoonLake Immunotherapeutics Confirms Investor Day Webcast Schedule With Open Q&A Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2613273445","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613273445?lang=en_us&edition=fundamental","pubTime":"2026-02-23 00:00","pubTimestamp":1771776016,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire  on February 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nNDL1rTmvW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","BK4139","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","BK4112","MLTX","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2613273702","title":"MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2613273702","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613273702?lang=en_us&edition=fundamental","pubTime":"2026-02-23 00:00","pubTimestamp":1771776000,"startTime":"0","endTime":"0","summary":"In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/22/3242267/0/en/MoonLake-Announces-Positive-Topline-Results-from-its-Phase-2-Clinical-Trial-of-Sonelokimab-in-Axial-Spondyloarthritis-and-Reports-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","BK4214","MLTX","LU1169590202.USD","MDA","AN","AS","ACR","BK4110","LU1169589451.USD","BK4139","SIJ"],"gpt_icon":0},{"id":"2612260700","title":"MoonLake Immunotherap Is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2612260700","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612260700?lang=en_us&edition=fundamental","pubTime":"2026-02-20 22:43","pubTimestamp":1771598580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 09:43 ET (14:43 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708994859.HKD","LU0310800379.SGD","BK4207","MLTX","LU1267930573.SGD","LU0128525929.USD","BK4139","LU0029864427.USD"],"gpt_icon":0},{"id":"2612262348","title":"RBC Raises Price Target on MoonLake Immunotherapeutics to $12 From $10, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2612262348","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612262348?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:07","pubTimestamp":1771592825,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) has an average rating of overweight and mean price target of $22.21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic rese","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLTX"],"gpt_icon":0},{"id":"2612610412","title":"MoonLake Immunotherapeutics (MLTX) Gets a Hold from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2612610412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612610412?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:17","pubTimestamp":1771589868,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Hold rating on MoonLake Immunotherapeutics today and set a price target of $12.00. Abrahams covers ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/moonlake-immunotherapeutics-mltx-gets-a-hold-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/moonlake-immunotherapeutics-mltx-gets-a-hold-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU0128525929.USD","MLTX","LU0310800379.SGD","LU0708994859.HKD","LU0029864427.USD","LU1267930573.SGD","BK4139"],"gpt_icon":0},{"id":"2610642341","title":"Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610642341","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610642341?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:00","pubTimestamp":1770724800,"startTime":"0","endTime":"0","summary":"Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership. Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis. Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe. \"Welcoming Ben to the Imagene team is the next step in executing our plans to create a focused, clinically excellent company. Ben's expertise in autoimmune and inflammatory diseases within and beyond medical dermatology, including his previous work on OX40 signaling inhibitors, is an incredible asset for our program. A recognized people leader, Ben will build and lead our clinical team, which will be essential as we focus on the execution of our Phase 2b ADAPTIVE trial in AD.\" commented Kristin Yarema, PhD, Chief Executive Officer of Imagene.\"Imagene has a compelling opportunity to make meaningful advances for pa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4139","BK4007","BK4132","IMA","MLTX","PBIB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":0.0388},{"period":"1month","weight":0.1475},{"period":"3month","weight":0.3188},{"period":"6month","weight":-0.6679},{"period":"1year","weight":-0.5557},{"period":"ytd","weight":0.3809}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.01118},{"month":2,"riseRate":0.5,"avgChangeRate":0.09112},{"month":3,"riseRate":0.6,"avgChangeRate":0.026866},{"month":4,"riseRate":0.2,"avgChangeRate":-0.112596},{"month":5,"riseRate":0.4,"avgChangeRate":0.086858},{"month":6,"riseRate":0.8,"avgChangeRate":0.175967},{"month":7,"riseRate":0.6,"avgChangeRate":0.073307},{"month":8,"riseRate":0.6,"avgChangeRate":0.090179},{"month":9,"riseRate":0.4,"avgChangeRate":-0.166769},{"month":10,"riseRate":0.6,"avgChangeRate":0.061028},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.079459}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}